JP2013528174A - オリゴベンズアミド化合物およびそれらの使用 - Google Patents

オリゴベンズアミド化合物およびそれらの使用 Download PDF

Info

Publication number
JP2013528174A
JP2013528174A JP2013512048A JP2013512048A JP2013528174A JP 2013528174 A JP2013528174 A JP 2013528174A JP 2013512048 A JP2013512048 A JP 2013512048A JP 2013512048 A JP2013512048 A JP 2013512048A JP 2013528174 A JP2013528174 A JP 2013528174A
Authority
JP
Japan
Prior art keywords
compound
alkyl
alkenyl
arylalkyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013512048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528174A5 (enExample
Inventor
ジュン‐モ アーン
ガネーシュ ラジ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2013528174A publication Critical patent/JP2013528174A/ja
Publication of JP2013528174A5 publication Critical patent/JP2013528174A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/06—Compounds containing nitro groups bound to a carbon skeleton having nitro groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2013512048A 2010-05-28 2011-05-27 オリゴベンズアミド化合物およびそれらの使用 Pending JP2013528174A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34955510P 2010-05-28 2010-05-28
US61/349,555 2010-05-28
PCT/US2011/038395 WO2011150360A1 (en) 2010-05-28 2011-05-27 Oligo-benzamide compounds and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016122278A Division JP6385986B2 (ja) 2010-05-28 2016-06-21 オリゴベンズアミド化合物およびそれらの使用

Publications (2)

Publication Number Publication Date
JP2013528174A true JP2013528174A (ja) 2013-07-08
JP2013528174A5 JP2013528174A5 (enExample) 2014-07-10

Family

ID=45004429

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013512048A Pending JP2013528174A (ja) 2010-05-28 2011-05-27 オリゴベンズアミド化合物およびそれらの使用
JP2016122278A Active JP6385986B2 (ja) 2010-05-28 2016-06-21 オリゴベンズアミド化合物およびそれらの使用
JP2018097720A Pending JP2018131459A (ja) 2010-05-28 2018-05-22 オリゴベンズアミド化合物およびそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016122278A Active JP6385986B2 (ja) 2010-05-28 2016-06-21 オリゴベンズアミド化合物およびそれらの使用
JP2018097720A Pending JP2018131459A (ja) 2010-05-28 2018-05-22 オリゴベンズアミド化合物およびそれらの使用

Country Status (14)

Country Link
US (3) US20130231385A1 (enExample)
EP (1) EP2575453B1 (enExample)
JP (3) JP2013528174A (enExample)
KR (1) KR20130115108A (enExample)
CN (1) CN102958364A (enExample)
AU (1) AU2011258009B2 (enExample)
BR (1) BR112012030298A2 (enExample)
CA (1) CA2800811C (enExample)
CL (1) CL2012003322A1 (enExample)
CO (1) CO6640301A2 (enExample)
EA (1) EA201291460A1 (enExample)
MX (1) MX2012013855A (enExample)
SG (1) SG186076A1 (enExample)
WO (1) WO2011150360A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515445A (ja) * 2015-05-18 2018-06-14 ネッレ セラピューティクス リミテッドＮｅｒｒｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 性ホルモン依存性疾患を治療するためのｎｋ−１／ｎｋ−３受容体デュアルアンタゴニスト
JP2024178254A (ja) * 2018-12-03 2024-12-24 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201291460A1 (ru) 2010-05-28 2013-11-29 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Олигобензамидные соединения и их применение
AU2012273182A1 (en) * 2011-06-21 2014-01-16 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
WO2013078288A1 (en) * 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds for use in treating cancers
WO2013078277A1 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CA2998170C (en) 2015-09-15 2023-10-03 Savage Medical, Inc. Devices and methods for anchoring a sheath in a tissue cavity
USD874674S1 (en) * 2016-10-17 2020-02-04 Brandcore Limited Vibrator
US20250114313A1 (en) * 2022-02-11 2025-04-10 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044379A2 (en) * 2004-10-15 2006-04-27 University Of North Carolina At Chapel Hill Novel curcumin analogues and uses thereof
WO2008112938A2 (en) * 2007-03-13 2008-09-18 New England Medical Center Hospitals, Inc. Composition and method for the treatment of diseases affected by a peptide receptor
WO2009055053A2 (en) * 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
WO2009105214A2 (en) * 2008-02-22 2009-08-27 Radius Health, Inc. Selective androgen receptor modulators
WO2010015212A1 (zh) * 2008-08-07 2010-02-11 浙江海正药业股份有限公司 一种对δ亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1903899A (en) 1933-04-18 Cabboxylic acid abylides oe the benzene sebies and process oe making
US3951914A (en) 1974-07-30 1976-04-20 E. I. Du Pont De Nemours And Company Process for preparing poly(1,4-benzamide) in cyclic sulfone media
US5212203A (en) 1986-01-21 1993-05-18 Centre International De Recherches Dermatogologiques (C.I.R.D.) Aromatic benzamido compounds; their preparation and their use in human or veterinary medicine or in cosmetic preparations
US5734081A (en) 1994-08-05 1998-03-31 Warner-Lambert Company Arylthio compounds
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
JP2007505118A (ja) * 2003-09-10 2007-03-08 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体調節剤としての１７−複素環−４−アザステロイド誘導体
WO2005081898A2 (en) 2004-02-20 2005-09-09 The Trustees Of The University Of Pennsylvania Binding peptidomimetics and uses of the same
US20070248535A1 (en) 2005-02-07 2007-10-25 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity
CA2629136C (en) 2005-11-08 2016-03-08 Choongwae Pharma Corporation .alpha.-helix mimetics and method relating to the treatment of cancer stem cells
US8236983B2 (en) 2008-03-13 2012-08-07 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by apoptosis
CN104474529A (zh) 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
JP5657549B2 (ja) 2008-10-17 2015-01-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 癌の阻害剤としてのｍｕｃ−１細胞質ドメインペプチド
EP2391372A4 (en) 2009-01-30 2013-07-03 Bayer Healthcare Llc ESTROGENIC RECEPTOR-BASED CANCER TREATMENT METHODS BY INHIBITING X1 BOXING BINDING PROTEIN (XBP1)
KR20120095402A (ko) 2009-10-23 2012-08-28 파나셀라 랩스, 아이엔씨. 안드로겐 수용체 양성 암의 치료 방법
EA201291460A1 (ru) * 2010-05-28 2013-11-29 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Олигобензамидные соединения и их применение
WO2013078277A1 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
WO2013078288A1 (en) * 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds for use in treating cancers

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044379A2 (en) * 2004-10-15 2006-04-27 University Of North Carolina At Chapel Hill Novel curcumin analogues and uses thereof
WO2008112938A2 (en) * 2007-03-13 2008-09-18 New England Medical Center Hospitals, Inc. Composition and method for the treatment of diseases affected by a peptide receptor
WO2008112941A1 (en) * 2007-03-13 2008-09-18 Board Of Regents The University Of Texas System Composition and method for the treatment of diseases affected by a peptide receptor
WO2008112939A2 (en) * 2007-03-13 2008-09-18 Board Of Regents, The University Of Texas System Composition and method for making oligo-benzamide compounds
US20090012141A1 (en) * 2007-03-13 2009-01-08 Board Of Regents, The University Of Texas System Composition and Method for Making Oligo-Benzamide Compounds
WO2009055053A2 (en) * 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
WO2009105214A2 (en) * 2008-02-22 2009-08-27 Radius Health, Inc. Selective androgen receptor modulators
WO2010015212A1 (zh) * 2008-08-07 2010-02-11 浙江海正药业股份有限公司 一种对δ亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 49(4), JPN6015011805, 8 January 2010 (2010-01-08), pages 736 - 739, ISSN: 0003039460 *
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 131(15), JPN6015011806, 2009, pages 5564 - 5572, ISSN: 0003039461 *
ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 6(1), JPN6015011809, 2008, pages 138 - 146, ISSN: 0003039462 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515445A (ja) * 2015-05-18 2018-06-14 ネッレ セラピューティクス リミテッドＮｅｒｒｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 性ホルモン依存性疾患を治療するためのｎｋ−１／ｎｋ−３受容体デュアルアンタゴニスト
JP2024178254A (ja) * 2018-12-03 2024-12-24 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用
JP7770716B2 (ja) 2018-12-03 2025-11-17 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用

Also Published As

Publication number Publication date
JP2017019769A (ja) 2017-01-26
JP6385986B2 (ja) 2018-09-05
SG186076A1 (en) 2013-01-30
US20130231385A1 (en) 2013-09-05
US9856206B2 (en) 2018-01-02
MX2012013855A (es) 2013-04-08
BR112012030298A2 (pt) 2015-09-29
EP2575453A1 (en) 2013-04-10
EA201291460A1 (ru) 2013-11-29
EP2575453A4 (en) 2015-12-23
US20180230087A1 (en) 2018-08-16
AU2011258009A1 (en) 2013-01-10
CO6640301A2 (es) 2013-03-22
EP2575453B1 (en) 2018-08-01
CN102958364A (zh) 2013-03-06
CL2012003322A1 (es) 2014-03-28
CA2800811C (en) 2019-02-26
JP2018131459A (ja) 2018-08-23
WO2011150360A1 (en) 2011-12-01
US20160130217A1 (en) 2016-05-12
AU2011258009B2 (en) 2016-04-21
KR20130115108A (ko) 2013-10-21
US10618869B2 (en) 2020-04-14
CA2800811A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
JP6385986B2 (ja) オリゴベンズアミド化合物およびそれらの使用
US9072705B2 (en) Oligo-benzamide compounds and their use in treating cancers
Guo et al. Chinese guidelines on the diagnosis and treatment of melanoma (2015 edition)
Pinkerton et al. Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators
TWI826395B (zh) 以藥草萃取物及其組成物抑制雄性素受體
US10682388B2 (en) Targeting of PELP1 in cancer therapy
US8835493B2 (en) Oligo-benzamide compounds for use in treating cancers
Serrano et al. Progress in chemoprevention of breast cancer
Zhang et al. Controversies in the management of endometrial carcinoma
US20250114313A1 (en) Oligo-benzamide analogs and their use in cancer treatment
Alkheilewi Characterisation of Androgen Receptor Variants in Breast Cancer and the Development of Thieno [2, 3-b] Pyridines as Novel Anti-Cancer Compounds
Iglesias et al. Gynecologic Oncology: Clinical Practice and Surgical Atlas
Armstrong The current status of adjuvant hormonal therapy combined with radiation therapy for localised prostate cancer
Śliwińska et al. Endometrial cancer in patients with breast carcinoma treated with tamoxifen: report of two cases and the literature overview
Doddamani et al. Prostate Cancer-What's New?
McCracken et al. Diagnosis and management of prostate cancer in the older man
Hadi To Evaluate the Safety and Efficacy of Low Dose Mifepristone in Medical Management of Uterine Leiomyoma in Karnataka Institute of Medical Sciences, Hubli
Tulunay et al. 894 Primary Ovarian Carcinosarcomas
Lehnen CNS, GPN, RNP, PhD. National PRO-Irish Practice Nurses Association

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150330

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150929

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160222